Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 124 clinical trials
Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations

This trial studies how well a video-based intervention works in helping participants encourage their families to get tested for BRCA gene mutations. Testing in families with BRCA gene mutations can allow for risk management and reduction with the overall goal of reducing cancer burden. Video-based intervention sent via text messages …

Accepts healthy volunteers
  • 0 views
  • 11 Mar, 2022
  • 1 location
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP

carcinoma
BRCA1
BRCA2
tumor cells
neutrophil count
  • 0 views
  • 20 Sep, 2022
  • 129 locations
A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

inhibitors has been demonstrated in patients with genomic features associated with HRD, even in the absence of germline BRCA1 or BRCA2 mutations. These results suggest that the presence of HRD itself is the

anticoagulants
primary cancer
EGFR
BRCA1
platelet count
  • 0 views
  • 09 Mar, 2022
  • 1 location
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

The primary objetive is to assess the capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1). The

her2/neu-negative breast cancer
advanced breast cancer
BRCA1
HER2
erbb2
  • 0 views
  • 04 May, 2022
  • 2 locations
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA)

BRCA1, BRCA2 or PALB2 inactivating DNA mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily

  • 14 views
  • 10 Apr, 2022
  • 11 locations
Functional Analysis of BRCAness

PARP inhibitors are most effective in homologous recombinant (HR) deficient tumors. There are clear indications that besides BRCA1 or BRCA2 mutated EOC, there is an additional group of EOC

  • 0 views
  • 09 Apr, 2021
  • 3 locations
Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia? (PROFAS)

Many surgical guidelines promote the removal of the pectoral fascia in mastectomies for invasive breast cancer, but there is no evidence to support this statement in (bilateral) prophylactic mastectomies. Reported wound-related local complications following mastectomy include seroma, flap necrosis, infection, hematoma, and nerve injury. Seroma causes discomfort and may delay …

cancer
  • 0 views
  • 03 Jun, 2022
  • 1 location
  • 0 views
  • 29 Jul, 2021
  • 1 location
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients

germline mutations in genes, such as BRCA1, BRCA2 and PALB2. The cumulative breast cancer risk for BRCA1, BRCA2 or PALB2 mutation carriers was high. Besides the increased breast cancer risk for the

lumpectomy
BRCA1
hormone therapy
BRCA2
mastectomy
  • 0 views
  • 25 Jul, 2021
  • 7 locations
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.

. Index cases will be enrolled consecutively from patients attending an appointment at one of the Unicancer centres, with no other inclusion criteria, and offered a BRCA1/2 analysis as part of their care

  • 1 views
  • 22 Jul, 2021
  • 1 location